← Back to patent-cliff list
ACC-006
Tier C — Watch / tradeACC-006
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：mTOR, SHH
Indications (approved)：Non-small cell lung cancer, Solid tumour
Regional status
US
-
EU
-
China
Phase II
2020-08-24
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of ACC-006?
Approved indications include: Non-small cell lung cancer, Solid tumour.
When does the ACC-006 patent expire?
No public expiry year is available for ACC-006 yet; this page updates once verified.
How do I get a quote for ACC-006 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06